Mon.Jan 01, 2024

article thumbnail

Alcohol Intervention in People With HIV Reduced Alcohol Use, Did Not Affect Viral Suppression

Pharmacy Times

Because alcohol is a driver of HIV-associated comorbidities, the reduction interventions may improve the health of people with HIV.

152
152
article thumbnail

Lawsuit claims J&J illegally delayed Stelara biosimilars

pharmaphorum

A lawsuit in the US is accusing Johnson & Johnson of unlawfully delaying the onset of biosimilar competition to its immunology blockbuster Stelara beyond its US patent expiry date.

109
109
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Venetoclax Improves Gap in Racial Overall Survival Disparity in Patients with AML

Pharmacy Times

According to the findings, the use of venetoclax, as well as other new therapies, improved overall survival from 28.6% to 45.3% in non-Hispanic Black patients with AML.

129
129
article thumbnail

Magazine: Pharma’s path to Net Zero: Targeting Scope 3 emissions

Pharmaceutical Technology

In this issue: Pharma’s efforts to curb Scope 3 emissions, understanding European Pharmaceutical legislation, and looking back at the pharma industry’s performance in 2023.

98
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Roche bolsters diagnostics with $295m LumiraDx deal

pharmaphorum

Roche has agreed a $295 million deal to buy a point-of-care diagnostics platform from LumiraDx, which recently went into administration

109
109
article thumbnail

Happy New Year!

OctariusRx

Happy New Year! New Year’s Day is the first page in a blank book, so let’s write an amazing story! We hope 2023 was a great year for everyone and that 2024 holds success and good fortune in all endeavors you pursue. 2003 was an incredible year for the OctariusRx team and we owe it all to our clients, family, and friends. Thank you for being part of our journey!

89

More Trending

article thumbnail

Are You Ready for Inspection?

BioPharm

Reviewing regulatory documents, such as 483 forms and Warning Letters, can aid in determining a facility’s inspection readiness, says Siegfried Schmitt, vice president, Technical at Parexel.

article thumbnail

8 Must-Do Strength Exercises to Stay Fit In Your 40’s

Dr. Jamie Hardy: The Lifestyle Pharmacist

As we age, maintaining strength and fitness becomes increasingly important for overall health and well-being. Regular exercise, particularly strength training, can help preserve muscle mass, improve bone density, enhance mobility, and boost metabolism. If you’re in your 40s and looking to stay fit and active, incorporating these eight strength exercises into your routine will help you maintain strength, agility, and vitality. 1.

article thumbnail

Drug Store News Events

Drug Store News

Don't miss DSN's upcoming events for 2024. Our event programs offer the latest industry content, top-tier speakers, networking opportunities, and more.

52
article thumbnail

The Pros and Cons of Adherent Versus Suspension Cell Culture

BioPharm

Both adherent and suspension cell culture approaches have their pros and cons, which must be considered for process development.

52
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Reimbursement Precipitating Shortages

BioPharm

GSI shortages result from how hospitals buy GSI drugs, and the underinvestment in manufacturing operations that follow.

article thumbnail

Right the First Time: Bioreactor Scale and Design Translation

BioPharm

The authors give an overview of scaling approaches and present good scaling practices for the biopharma industry.

52
article thumbnail

Navigating Challenges in Cell Therapy Potency Assays

BioPharm

Developing cell-based potency assays for cell therapies requires meticulous coordination.

52
article thumbnail

From Vaccines to Oncology and Beyond: Tracking mRNA’s Progress

BioPharm

The success of mRNA-based vaccines paves the way for mRNA in oncology and beyond.

article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Selecting Chromatography Resins for Bispecific Antibody Purification

BioPharm

Product and process understanding are essential to effective resin selection.

52
article thumbnail

Leap Year

BioPharm

Revolutionary therapies restructure pharmaceutical manufacturing.

52
article thumbnail

New Therapies Cry Out for New Skills

BioPharm

There are positive indications for future growth.

52